Sec.		Sec.
350.	Vitamins and minerals.	360l. Postmarket surveillance.
350a.	Infant formulas.	360m. Accredited persons.
350b.	New dietary ingredients.	360n. Priority review to encourage treatments for
350c.	Maintenance and inspection of records.	tropical diseases.
350d. 350e.	Registration of food facilities. Sanitary transportation practices.	360n-1. Priority review for qualified infectious disease products.
350e.	Reportable food registry.	ease products.
350g.	Hazard analysis and risk-based preventive	PART B—DRUGS FOR RARE DISEASES OR CONDITIONS
	controls.	360aa. Recommendations for investigations of drugs
350h.	Standards for produce safety.	for rare diseases or conditions.
350i.	Protection against intentional adulteration.	360bb. Designation of drugs for rare diseases or con-
350j.	Targeting of inspection resources for domes-	ditions.
	tic facilities, foreign facilities, and ports of	360cc. Protection for drugs for rare diseases or con-
350k.	entry; annual report. Laboratory accreditation for analyses of	ditions.
550K.	foods.	360dd. Open protocols for investigations of drugs for
3501.	Mandatory recall authority.	rare diseases or conditions.
350l-1.	Annual report to Congress.	360ee. Grants and contracts for development of drugs for rare diseases and conditions.
SI	UBCHAPTER V—DRUGS AND DEVICES	360ff. Priority review to encourage treatments for
		rare pediatric diseases.
	PART A—DRUGS AND DEVICES	•
351.	Adulterated drugs and devices.	PART C—ELECTRONIC PRODUCT RADIATION CONTROL
352.	Misbranded drugs and devices.	360hh. Definitions.
353.	Exemptions and consideration for certain	360ii. Program of control.
0500	drugs, devices, and biological products.	360jj. Studies by Secretary.
353a. 353a–1.	Pharmacy compounding. Enhanced communication.	360kk. Performance standards for electronic prod-
353b.	Outsourcing facilities.	ucts. 360ll. Notification of defects in and repair or re-
353c.	Prereview of television advertisements.	placement of electronic products.
354.	Veterinary feed directive drugs.	360mm. Imports.
355.	New drugs.	360nn. Inspection, records, and reports.
355-1.	Risk evaluation and mitigation strategies.	36000. Prohibited acts.
355a.	Pediatric studies of drugs.	360pp. Enforcement.
355b.	Adverse-event reporting.	360qq. Repealed.
355c.	Research into pediatric uses for drugs and bi- ological products.	360rr. Federal-State cooperation.
355c-1.	Report.	360ss. State standards.
355d.	Internal committee for review of pediatric	PART D—DISSEMINATION OF TREATMENT INFORMATION
	plans, assessments, deferrals, deferral ex-	360aaa to 360aaa-6. Omitted
	tensions, and waivers.	
355e.	Pharmaceutical security.	PART E—GENERAL PROVISIONS RELATING TO DRUGS
355f.	Extension of exclusivity period for new quali-	AND DEVICES
356.	fied infectious disease products.	0001-1
550.		360bbb. Expanded access to unapproved therapies and
	Expedited approval of drugs for serious or life-threatening diseases or conditions	diagnostics.
356–1.	life-threatening diseases or conditions.	diagnostics. 360bbb-1. Dispute resolution.
356–1.		diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products.
356a.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in
356a. 356b.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies.
356a.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the produc-	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products.
356a. 356b. 356c.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies.
356a. 356b. 356c. 356c-1.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use.
356a. 356b. 356c. 356c-1. 356d.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships.
356a. 356b. 356c. 356c-1.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication.
356a. 356b. 356c. 356c-1. 356d. 356e.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification.
356a. 356b. 356c. 356c-1. 356d. 356e. 356f. 357. 358.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3a. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification.
356a. 356b. 356c. 356c-1. 356d. 356e. 356f. 357. 358. 359.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic
356a. 356b. 356c. 356c-1. 356d. 356e. 356f. 357. 358. 359.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments.
356a. 356b. 356c. 356c-1. 356d. 356e. 357. 358. 359. 360.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials.
356a. 356b. 356c. 356c-1. 356d. 356e. 357. 358. 359. 360. 360a. 360a-1.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments.
356a. 356b. 356c. 356c-1. 356d. 356e. 356f. 357. 358. 359. 360a. 360a-1. 360b.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. New animal drugs.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from out-
356a. 356b. 356c. 356c-1. 356d. 356e. 357. 358. 359. 360. 360a. 360a-1.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trials guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States.
356a. 356b. 356c. 356c-1. 356d. 356e. 356f. 357. 358. 359. 360a. 360a-1. 360b.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. New animal drugs.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion.
356a. 356b. 356c-1. 356c. 356e. 356f. 357. 358. 359. 360. 360a. 360a1. 360b. 360c1. 360c1.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting. Performance standards.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States.
356a. 356b. 356c-1. 356c-1. 356d. 356e. 356f. 357. 358. 360. 360a. 360a-1. 360b. 360c-1. 360d. 360e.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting. Performance standards. Premarket approval.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion. PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES
356a. 356b. 356c-1. 356d. 356e. 356f. 357. 358. 359. 360a. 360a-1. 360b. 360c-1. 360c-1. 360c.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting. Performance standards. Premarket approval. Pediatric uses of devices.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion. PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for
356a. 356b. 356c-1. 356d. 356e. 357. 358. 359. 360. 360a. 360a-1. 360b. 360c-1. 360c-1. 360d.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting. Performance standards. Premarket approval. Pediatric uses of devices. Banned devices.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion. PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for minor use and minor species.
356a. 356b. 356c-1. 356d. 356e. 356e. 356f. 357. 358. 359. 360a. 360a. 360a. 360c. 360c-1. 360d. 360e. 360e. 360e-1. 360f. 360g.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting. Performance standards. Premarket approval. Pediatric uses of devices. Banned devices. Judicial review.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion. PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for minor use and minor species. 360ccc-1. Index of legally marketed unapproved new
356a. 356b. 356c-1. 356d. 356e. 357. 358. 359. 360. 360a. 360a-1. 360b. 360c-1. 360c-1. 360d.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting. Performance standards. Premarket approval. Pediatric uses of devices. Banned devices. Judicial review. Agency documentation and review of signifi-	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion. PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for minor use and minor species.
356a. 356b. 356c-1. 356c-1. 356d. 356e. 357. 358. 359. 360a. 360a-1. 360b. 360c-1. 360c. 360c-1. 360d. 360e-1. 360e.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting. Performance standards. Premarket approval. Pediatric uses of devices. Banned devices. Judicial review. Agency documentation and review of significant decisions regarding devices.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion. PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for minor use and minor species. 360ccc-1. Index of legally marketed unapproved new animal drugs for minor species.
356a. 356b. 356c-1. 356d. 356e. 356e. 356f. 357. 358. 359. 360a. 360a. 360a. 360c. 360c-1. 360d. 360e. 360e. 360e-1. 360f. 360g.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting. Performance standards. Premarket approval. Pediatric uses of devices. Banned devices. Judicial review. Agency documentation and review of signifi-	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion. PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for minor use and minor species. 360ccc-1. Index of legally marketed unapproved new animal drugs for minor use or minor species.
356a. 356b. 356c-1. 356d. 356e. 356e. 357. 358. 359. 360a. 360a. 360a. 360c. 360c-1. 360d. 360e. 360e-1. 360f. 360g. 360g-1.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting. Performance standards. Premarket approval. Pediatric uses of devices. Banned devices. Judicial review. Agency documentation and review of significant decisions regarding devices. Notification and other remedies. Program to improve the device recall system. Records and reports on devices.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion. PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for minor use and minor species. 360ccc-1. Index of legally marketed unapproved new animal drugs for minor species. 360ccc-2. Designated new animal drugs for minor use or minor species.
356a. 356b. 356c-1. 356d. 356e. 356e. 357. 358. 359. 360a. 360a. 360a. 360c-1. 360d. 360e. 360e. 360e. 360e. 360e. 360e. 360e. 360h. 360h.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting. Performance standards. Premarket approval. Pediatric uses of devices. Banned devices. Judicial review. Agency documentation and review of significant decisions regarding devices. Notification and other remedies. Program to improve the device recall system. Records and reports on devices. General provisions respecting control of de-	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion. PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for minor use and minor species. 360ccc-1. Index of legally marketed unapproved new animal drugs for minor species. 360ccc-2. Designated new animal drugs for minor use or minor species. PART G—MEDICAL GASES 360ddd. Definitions.
356a. 356b. 356c-1. 356d. 356e. 356e. 357. 358. 359. 360a. 360a-1. 360b. 360c-1. 360d. 360e-1. 360f. 360g-1. 360f. 360g-1.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting. Performance standards. Premarket approval. Pediatric uses of devices. Banned devices. Judicial review. Agency documentation and review of significant decisions regarding devices. Notification and other remedies. Program to improve the device recall system. Records and reports on devices. General provisions respecting control of devices intended for human use.	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion. PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for minor use and minor species. 360ccc-1. Index of legally marketed unapproved new animal drugs for minor species. 360ccc-2. Designated new animal drugs for minor use or minor species. PART G—MEDICAL GASES 360ddd. Definitions. 360ddd-1. Regulation of medical gases.
356a. 356b. 356c-1. 356d. 356e. 356e. 357. 358. 359. 360a. 360a. 360a. 360c. 360c-1. 360d. 360e. 360e-1. 360f. 360g. 360g-1.	life-threatening diseases or conditions. Accelerated approval of priority countermeasures. Manufacturing changes. Reports of postmarketing studies. Discontinuance or interruption in the production of life-saving drugs. Annual reporting on drug shortages. Coordination; task force and strategic plan. Drug shortage list. Hospital repackaging of drugs in shortage. Repealed. Authority to designate official names. Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. Clinical trial guidance for antibiotic drugs. Clinical trials. New animal drugs. Classification of devices intended for human use. Reporting. Performance standards. Premarket approval. Pediatric uses of devices. Banned devices. Judicial review. Agency documentation and review of significant decisions regarding devices. Notification and other remedies. Program to improve the device recall system. Records and reports on devices. General provisions respecting control of de-	diagnostics. 360bbb-1. Dispute resolution. 360bbb-2. Classification of products. 360bbb-3. Authorization for medical products for use in emergencies. 360bbb-3a.Emergency use of medical products. 360bbb-3b.Products held for emergency use. 360bbb-4. Countermeasure development, review, and technical assistance. 360bbb-5. Critical Path Public-Private Partnerships. 360bbb-6. Risk communication. 360bbb-7. Notification. 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments. 360bbb-8a.Optimizing global clinical trials. 360bbb-8b.Use of clinical investigation data from outside the United States. 360bbb-8c.Patient participation in medical product discussion. PART F—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES 360ccc. Conditional approval of new animal drugs for minor use and minor species. 360ccc-1. Index of legally marketed unapproved new animal drugs for minor species. 360ccc-2. Designated new animal drugs for minor use or minor species. PART G—MEDICAL GASES 360ddd. Definitions.

Sec. Part H-	-Pharmaceutical Distribution Supply Chain	Sec. 379j–22.	Reauthorization; reporting requirements.	
360eee.	Definitions.	0.00 22.	SUBPART 6—FEES RELATED TO FOOD	
360eee–1.	Requirements.	379j–31.	Authority to collect and use fees.	
360eee–2.	National standards for prescription drug wholesale distributors.	-	·	
360eee–3.	National standards for third-party logistics		PART 7—FEES RELATING TO GENERIC DRUGS	
360eee–4.	providers. Uniform national policy.	379j–41. 379j–42.	Definitions. Authority to assess and use human generic	
	SUBCHAPTER VI—COSMETICS	070: 40	drug fees.	
361.	Adulterated cosmetics.	379j–43.	Reauthorization; reporting requirements.	
362. 363.	Misbranded cosmetics. Regulations making exemptions.	SUBPAR	T 8—FEES RELATING TO BIOSIMILAR BIOLOGICAL PRODUCTS	
364.	Repealed.	379j–51.	Definitions.	
SUI	BCHAPTER VII—GENERAL AUTHORITY	379j–52.	Authority to assess and use biosimilar bio-	
PAR	r A—General Administrative Provisions	379j-53.	logical product fees. Reauthorization; reporting requirements.	
371.	Regulations and hearings.	SUBPART	7 9—FEES RELATING TO OUTSOURCING FACILITIES	
372. 372a.	Examinations and investigations. Transferred.	379j-61.	Definitions.	
373.	Records.	379j–62.	Authority to assess and use outsourcing facil-	
374. 374a.	Inspection. Inspections relating to food allergens.		ity fees.	
375.	Publicity.		PART D—INFORMATION AND EDUCATION	
376.	Examination of sea food on request of packer; marking food with results; fees; penalties.	379k. 379k–1.	Information system. Electronic format for submissions.	
377.	Revision of United States Pharmacopoeia; development of analysis and mechanical and	379 <i>l</i> .	Education.	
	physical tests.	Р	ART E—ENVIRONMENTAL IMPACT REVIEW	
378. 379.	Advertising of foods. Confidential information.	379o.	Environmental impact.	
379a.	Presumption of existence of jurisdiction.	Part F-	—NATIONAL UNIFORMITY FOR NONPRESCRIPTION	
379b.	Consolidated administrative and laboratory facility.		AND PREEMPTION FOR LABELING OR PACKAG-	
379c.	Transferred.	379r.	COSMETICS National uniformity for nonprescription	
379d.	Automation of Food and Drug Administra- tion.	3191.	National uniformity for nonprescription drugs.	
379d–1.	Conflicts of interest.	379s.	Preemption for labeling or packaging of cosmetics.	
379d–2.	Policy on the review and clearance of sci- entific articles published by FDA employ-	PART G—SAFETY REPORTS		
379d–3.	ees. Streamlined hiring authority.	379v.	Safety report disclaimers.	
379d–4.	Reporting requirements.			
379d–5.	Guidance document regarding product promotion using the Internet.	Ра 379aa.	RT H—SERIOUS ADVERSE EVENT REPORTS	
	PART B—Colors	519aa.	Serious adverse event reporting for non- prescription drugs.	
379e.	Listing and certification of color additives for foods, drugs, devices, and cosmetics.	379aa–1.	Serious adverse event reporting for dietary supplements.	
	PART C—FEES	PART :	I—REAGAN-UDALL FOUNDATION FOR THE FOOD AND DRUG ADMINISTRATION	
SII	BPART 1—FREEDOM OF INFORMATION FEES	379dd.	Establishment and functions of the Founda-	
379f.	Recovery and retention of fees for freedom of		tion.	
	information requests.		Location of Foundation. Activities of the Food and Drug Administra-	
	SUBPART 2—FEES RELATING TO DRUGS		tion.	
379g. 379h.	Definitions.	SUB	CHAPTER VIII—IMPORTS AND EXPORTS	
379h-1.	Authority to assess and use drug fees. Fees relating to advisory review of prescrip-	381. 382.	Imports and exports. Exports of certain unapproved products.	
379h–2.	tion-drug television advertising. Reauthorization; reporting requirements.	383.	Office of International Relations.	
	SUBPART 3—FEES RELATING TO DEVICES	384. 384a.	Importation of prescription drugs. Foreign supplier verification program.	
379i.	Definitions.	384b.	Voluntary qualified importer program.	
379j.	Authority to assess and use device fees.	384c. 384d.	Inspection of foreign food facilities. Accreditation of third-party auditors.	
379j–1.	Reauthorization; reporting requirements.	384e.	Recognition of foreign government inspec-	
	SPART 4—FEES RELATING TO ANIMAL DRUGS	CI	tions. JBCHAPTER IX—TOBACCO PRODUCTS	
379j–11. 379j–12.	Definitions. Authority to assess and use animal drug fees.	387.	Definitions.	
379j–12.	Reauthorization; reporting requirements.	387a.	FDA authority over tobacco products.	
SUBPART 5—FEES RELATING TO GENERIC NEW ANIMAL				
SUBPAI		387a–1. 387b.	Final rule. Adulterated tobacco products.	
SUBPAI 379j–21.	RT 5—FEES RELATING TO GENERIC NEW ANIMAL DRUGS Authority to assess and use generic new ani-	387a-1. 387b. 387c. 387d.	Final rule. Adulterated tobacco products. Misbranded tobacco products. Submission of health information to the Sec-	

Sec.	
387e.	Annual registration.
387f.	General provisions respecting control of to-
	bacco products.
387f-1.	Enforcement action plan for advertising and
	promotion restrictions.
387g.	Tobacco product standards.
387h.	Notification and other remedies.
387i.	Records and reports on tobacco products.
387j.	Application for review of certain tobacco
	products.
387k.	Modified risk tobacco products.
387l.	Judicial review.
387m.	Equal treatment of retail outlets.
387n.	Jurisdiction of and coordination with the
	Federal Trade Commission.
3870.	Regulation requirement.
387p.	Preservation of State and local authority.
387q.	Tobacco Products Scientific Advisory Com-
	mittee.
387r.	Drug products used to treat tobacco depend-
	ence.
387s.	User fees.
387t.	Labeling, recordkeeping, records inspection.
387u.	Studies of progress and effectiveness.
	SUBCHAPTER X—MISCELLANEOUS
391.	Separability clause.
392.	Exemption of meats and meat food products.
393.	Food and Drug Administration.
393a.	Office of Pediatric Therapeutics.
394.	Scientific review groups.
395.	Loan repayment program.
396.	Practice of medicine.
397.	Contracts for expert review.
398.	Notices to States regarding imported food.
399.	Grants to enhance food safety.
399a.	Office of the Chief Scientist.
399b.	Office of Women's Health.
399c.	Improving the training of State, local, terri-
000.1	torial, and tribal food safety officials.
399d.	Employee protections.
399e.	Nanotechnology.

SUBCHAPTER I—SHORT TITLE

including racial subgroups.

Ensuring adequate information regarding

pharmaceuticals for all populations, par-

ticularly underrepresented subpopulations,

§ 301. Short title

399f.

This chapter may be cited as the Federal Food, Drug, and Cosmetic Act.

(June 25, 1938, ch. 675, §1, 52 Stat. 1040.)

EFFECTIVE DATE; POSTPONEMENT IN CERTAIN CASES

Act June 23, 1939, ch. 242, §§1, 2, 53 Stat. 853, 854, provided that:

"[SEC. 1] (a) The effective date of the following provisions of the Federal Food, Drug, and Cosmetic Act is hereby postponed until January 1, 1940: Sections 402(c) [342(c) of this title]; 403(e)(1) [343(e)(1) of this title]; 403(g), (h), (i), (j), and (k) [343(g) to (k) of this title]; 501(a), (4) [351(a)(4) of this title]; 502(b), (d), (e), (f), (g), and (h) [352(b), (d) to (h) of this title]; 601(e) [361(e) of this title]; and 602(b) [362(b) of this title]

"(b) The Secretary of Agriculture shall promulgate regulations further postponing to July 1, 1940[,] the effective date of the provisions of sections 403(e)(1) [343(e)(1) of this title]; 403(g), (h), (i), (j), and (k) [343(g) to (k)]; 502(b), (d), (e), (f), (g), and (h) [352(b), (d) to (h) of this title]; and 602(b) [362(b) of this title] of such Act with respect to lithographed labeling which was manufactured prior to February 1, 1939, and to containers bearing labeling which, prior to February 1, 1939, was lithographed, etched, stamped, pressed, printed, fused or blown on or in such containers, where compliance with such provisions would be unduly burdensome by

reason of causing the loss of valuable stocks of such labeling or containers, and where such postponement would not prevent the public interest being adequately served: Provided, That in no case shall such regulations apply to labeling which would not have complied with the requirements of the Food and Drugs Act of June 30, 1906, as amended.

"Sec. 2. (a) The provisions of section 8 [section 10 of this title], paragraph fifth, under the heading 'In the case of food:', of the Food and Drugs Act of June 30, 1906, as amended, and regulations promulgated thereunder, and all other provisions of such Act to the extent that they may relate to the enforcement of such section 8 [section 10 of this title] and of such regulations, shall remain in force until January 1, 1940.

"(b) The provisions of such Act of June 30, 1906, as amended, [sections 1 to 5, 7 to 15, and 372a of this title] to the extent that they impose, or authorize the imposition of, any requirement imposed by section 403(k) of the Federal Food, Drug, and Cosmetic Act [section 343(k) of this title], shall remain in force until January 1, 1940.

"(c) Notwithstanding the provisions of section 1 of this Act, such section shall not apply—
"(1) to the provisions of section 502(d) and (e) of the

"(1) to the provisions of section 502(d) and (e) of the Federal Food, Drug, and Cosmetic Act [352(d), (e) of this title], insofar as such provisions relate to any substance named in section 8 [section 10 of this title], paragraph second, under the heading 'In the case of drugs:', of the Food and Drugs Act of June 30, 1906, as amended, or a derivative of any such substance; or

"(2) to the provisions of section 502(b), (d), (e), (f), (g), and (h) of the Federal Food, Drug, and Cosmetic Act [352(b), (d) to (h) of this title], insofar as such provisions relate to drugs to which section 505 [355 of this title] of such Act applies."

EFFECTIVE DATE

Act June 25, 1938, ch. 675, §1002(a), formerly §902(a), 52 Stat. 1059; renumbered §1002(a), Pub. L. 111–31, div. A, title I, §101(b)(2), June 22, 2009, 123 Stat. 1784, provided that: "This Act [enacting this chapter and repealing sections 1 to 5 and 7 to 15 of this title], shall take effect twelve months after the date of its enactment [June 25] 1938]. The Federal Food and Drugs Act of June 30, 1906, as amended (U.S.C., 1934 ed., title 21, secs. 1-15), shall remain in force until such effective date, and, except as otherwise provided in this subsection, is hereby repealed effective upon such date: Provided, That the provisions of section 701 [section 371 of this title] shall become effective on the enactment of this Act, and thereafter the Secretary is authorized hereby to (1) conduct hearings and to promulgate regulations which shall become effective on or after the effective date of this Act as the Secretary shall direct, and (2) designate prior to the effective date of this Act food having common or usual names and exempt such food from the requirements of clause (2) of section 403(i) [section 343(i) of this title] for a reasonable time to permit the formulation, promulgation, and effective application of definitions and standards of identity therefor as provided by section 401 [section 341 of this title]: Provided further, That sections 502(j), 505, and 601(a) [sections 352(j), 355, 361(a), respectively of this title], and all other provisions of this Act to the extent that they may relate to the enforcement of such sections, shall take effect on the date of the enactment of this Act, except that in the case of a cosmetic to which the proviso of section 601(a) [section 361(a) of this title], relates, such cosmetic shall not, prior to the ninetieth day after such date of enactment, be deemed adulterated by reason of the failure of its label to bear the legend prescribed in such proviso: Provided further, That the Act of March 4, 1923 (U.S.C., 1934 ed., title 21, sec. 6 [section 321a of this title]; 42 Stat. 1500, ch. 268), defining butter and providing a standard therefor; the Act of July 24, 1919 (U.S.C., 1934 ed., title 21, sec. 10 [section 321b of this title]; 41 Stat. 271, ch. 26], defining wrapped meats as in package form; and the amendment to the Food and Drugs Act, section 10A, approved August 27, 1935 (U.S.C. 1934 ed.,